Associated Papers
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes.
Galka-Marciniak P et al.
Nucleic Acids Research, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A et al.
Biomarker Research, 2024
Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis.
Disel U et al.
The Oncologist, 2024
Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene-A Literature Review and Single-Center Experience.
Rekowska AK et al.
Biomedicines, 2024
Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population.
Sini MC et al.
Journal of Translational Medicine, 2024
Assessment of KRASG12C inhibitors for colorectal cancer.
Piazza GA et al.
Frontiers in Oncology, 2024
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.
Chour A et al.
Frontiers in Oncology, 2024
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J et al.
Pathology Oncology Research : Por, 2023
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M et al.
Current Treatment Options in Oncology, 2022
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.
Feng S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
Reita D et al.
Cancers, 2022
Regulation of GTPase function by autophosphorylation.
Johnson CW et al.
Molecular Cell, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer.
Ricciuti B et al.
Drugs in Context, 2022
Acquired Resistance to KRASG12C Inhibition in Cancer.
Awad MM et al.
The New England Journal of Medicine, 2021
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J et al.
Bmc Cancer, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer.
Baek JH et al.
Cancer Diagnosis & Prognosis, 0